Johnstone E - Search Results

1

Bromocriptine use is associated with decreased smoking rates.

Murphy MF, Hey K, Johnstone E, Munafo M, Walton R, Willis B, Harrison PJ. Murphy MF, et al. Among authors: johnstone e. Addict Biol. 2002 Jul;7(3):325-8. doi: 10.1080/13556210220139550. Addict Biol. 2002. PMID: 12126493

2

The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population.

Johnstone EC, Yudkin P, Griffiths SE, Fuller A, Murphy M, Walton R. Johnstone EC, et al. Addict Biol. 2004 Sep-Dec;9(3-4):221-6. doi: 10.1080/13556210412331292226. Addict Biol. 2004. PMID: 15511716

3

New directions in the genetic mechanisms underlying nicotine addiction.

Munafò M, Johnstone E, Murphy M, Walton R. Munafò M, et al. Among authors: johnstone e. Addict Biol. 2001 Apr;6(2):109-117. doi: 10.1080/13556210020040181. Addict Biol. 2001. PMID: 11341850

4

Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt.

Johnstone E, Hey K, Drury M, Roberts S, Welch S, Walton R, Murphy M. Johnstone E, et al. Addict Biol. 2004 Sep-Dec;9(3-4):227-32. doi: 10.1080/13556210412331312421. Addict Biol. 2004. PMID: 15511717

5

Association of the mu-opioid receptor gene with smoking cessation.

Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Munafò MR, et al. Among authors: johnstone ec. Pharmacogenomics J. 2007 Oct;7(5):353-61. doi: 10.1038/sj.tpj.6500432. Epub 2007 Jan 16. Pharmacogenomics J. 2007. PMID: 17224915 Clinical Trial.

6

Genetic testing: the future of smoking cessation therapy?

Johnstone EC, York EE, Walton RT. Johnstone EC, et al. Expert Rev Mol Diagn. 2002 Jan;2(1):60-8. doi: 10.1586/14737159.2.1.60. Expert Rev Mol Diagn. 2002. PMID: 11963809 Review.

7

Polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers: seeking confirmation of the association in a follow-up study.

Johnstone EC, Clark TG, Griffiths SE, Murphy MF, Walton RT. Johnstone EC, et al. Pharmacogenetics. 2002 Oct;12(7):585-7. doi: 10.1097/00008571-200210000-00012. Pharmacogenetics. 2002. PMID: 12360111 No abstract available.

8

Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT. Johnstone EC, et al. Pharmacogenetics. 2004 Feb;14(2):83-90. doi: 10.1097/00008571-200402000-00002. Pharmacogenetics. 2004. PMID: 15077009 Clinical Trial.

9

Smoking cessation, weight gain, and DRD4 -521 genotype.

Munafò MR, Murphy MF, Johnstone EC. Munafò MR, et al. Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):398-402. doi: 10.1002/ajmg.b.30289. Am J Med Genet B Neuropsychiatr Genet. 2006. PMID: 16526060

10

Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.

Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Johnstone EC, et al. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1065-9. doi: 10.1158/1055-9965.EPI-06-0936. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17548664 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

686 results

Search Page